Table 1.
Comparison of oral tolerance induction to OVA or peanut butter with different innate activators
| OVA‐specific antibody levels in plasma 1 week after boost | IgE | IgA | IgG1 | IgG2a |
|---|---|---|---|---|
| (A) Comparison between control, OVA‐tolerized, and FSL‐1‐treated tolerized groups (n = 10) | ||||
| Control | 59.23 ± 6.70 | 0.293 ± 0.067 | 5.12 ± 1.25 | 3.30 ± 1.32 |
| OVA tolerized | 11.59 ± 3.59*** | 0.186 ± 0.040 | 4.88 ± 1.84 | 2.65 ± 0.99 |
| OVA tolerized + FSL‐1 | 30.79 ± 6.38 | 0.453 ± 0.073 † | 5.30 ± 0.69 † | 3.38 ± 0.95 |
| (B) Comparison between control, OVA tolerized, and LPS‐treated tolerized groups (n = 14–15) | ||||
| Control | 28.87 ± 4.66 | 0.138 ± 0.045 | 4.23 ± 1.98 | 2.94 ± 2.26 |
| OVA tolerized | 9.59 ± 2.06*** | 0.038 ± 0.008 | 4.58 ± 0.88 | 2.93 ± 0.96 |
| OVA tolerized + LPS | 11.91 ± 2.60** | 0.197 ± 0.062 † | 4.80 ± 1.35 | 3.15 ± 1.31 |
| Peanut‐specific antibody levels in plasma 1 week after boost | ||||
|---|---|---|---|---|
| (C) Comparison between control, peanut butter tolerized, and Pam3CSK4‐treated tolerized groups (n = 10) | ||||
| Control | 0.241 ± 0.083 | 0.077 ± 0.023 | 0.199 ± 0.024 | 0.616 ± 0.075 |
| Peanut butter tolerized | 0.107 ± 0.093* | 0.010 ± 0.003* | 0.022 ± 0.009*** | 0.119 ± 0.049*** |
| Peanut butter tolerized + Pam3CSK4 | 0.011 ± 0.003** | 0.038 ± 0.012 | 0.115 ± 0.037 | 0.173 ± 0.049*** |
OVA‐specific antibody levels are expressed as mean ng/mL ± SEM (IgE), mean A490 ± SEM (IgA), or median –Log titre ± IR (IgG1, IgG2a) (A and B). IgE and IgA levels were compared between groups by anova followed by Bonferroni's Multiple Comparison test. IgG1 and IgG2a levels were compared between groups by Kruskal–Wallis test followed by Dunn's multiple comparison test. (C) Peanut‐specific antibody levels are expressed as mean A490 ± SEM. Antibody levels were compared between groups by anova followed by Bonferroni's multiple comparison test.
Significant differences following post‐test comparisons between tolerized groups and the corresponding control group are identified by ‘*’. *P < 0.05, **P < 0.01, ***P < 0.001.
Significant differences following post‐test comparisons between tolerized groups and tolerized + innate activator groups are represented by ‘†’. † P < 0.05.